Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Short-Term Debt issuances (2017 - 2025)

Myriad Genetics (MYGN) has disclosed Short-Term Debt issuances for 5 consecutive years, with $40.0 million as the latest value for Q1 2025.

  • Quarterly Short-Term Debt issuances fell 33.33% to $40.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $40.0 million through Dec 2025, down 66.67% year-over-year, with the annual reading at $40.0 million for FY2025, 66.67% down from the prior year.
  • Short-Term Debt issuances for Q1 2025 was $40.0 million at Myriad Genetics, up from $20.0 million in the prior quarter.
  • The five-year high for Short-Term Debt issuances was $60.0 million in Q1 2024, with the low at $20.0 million in Q2 2024.
  • Average Short-Term Debt issuances over 3 years is $34.3 million, with a median of $40.0 million recorded in 2023.
  • The sharpest move saw Short-Term Debt issuances plummeted 50.0% in 2024, then plummeted 33.33% in 2025.
  • Over 3 years, Short-Term Debt issuances stood at $40.0 million in 2023, then tumbled by 50.0% to $20.0 million in 2024, then soared by 100.0% to $40.0 million in 2025.
  • According to Business Quant data, Short-Term Debt issuances over the past three periods came in at $40.0 million, $20.0 million, and $20.0 million for Q1 2025, Q4 2024, and Q3 2024 respectively.